Global Personalized Medicine in Oncology Partnering Terms and Agreements 2010 to 2016

Description: The Global Personalized Medicine in Oncology Partnering Terms and Agreements 2010 to 2016 report provides comprehensive understanding and unprecedented access to the personalized medicine in oncology partnering agreements entered into by the worlds leading healthcare companies.

Comprehensive directory of personalized medicine in oncology deals since 2010
Personalized medicine in oncology contract documents
Personalized medicine in oncology agreement terms
Personalized medicine in oncology agreement structure
Top personalized medicine in oncology deals by value
Most active personalized medicine in oncology dealmakers

The Global Personalized Medicine in Oncology Partnering Terms and Agreements 2010 to 2016 report provides comprehensive understanding and unprecedented access to the personalized medicine in oncology partnering agreements entered into by the worlds leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter personalized medicine in oncology partnering deals. The majority of deals are discovery stage whereby the licensee obtains a right or an option right to license the licensors personalized medicine technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.

The initial chapters of this report provide an orientation of Personalized Medicine in Oncology dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in Personalized Medicine in Oncology dealmaking since 2010, including details of average headline, upfront, milestone and royalty terms.

Chapter 3 provides a review of the leading Personalized Medicine in Oncology deals since 2010. Deals are listed by headline value, signed by big pharma, most active Personalized Medicine in Oncology dealmaking companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive listing of the top 25 most active companies in Personalized Medicine in Oncology dealmaking with a brief summary followed by a comprehensive listing of Personalized Medicine in Oncology deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 5 provides a comprehensive and detailed review of Personalized Medicine in Oncology partnering deals signed and announced since Jan 2010, where a contract document is available in the public domain. The chapter is organized by company A-Z, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Chapter 7 provides a comprehensive and detailed review of Personalized Medicine in Oncology partnering deals signed and announced since Jan 2010. The chapter is organized by specific Personalized Medicine in Oncology technology type in focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided organized by Personalized Medicine in Oncology
partnering company A-Z, deal type definitions and Personalized Medicine in Oncology partnering agreements example. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Personalized Medicine in Oncology partnering and dealmaking since 2010.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Personalized Medicine in Oncology technologies and products.

Report scope

Global Personalized Medicine in Oncology Partnering Terms and Agreements 2010 to 2016 is intended to provide the reader with an in-depth understanding of the personalized medicine in oncology trends and structure of deals entered into by leading companies worldwide.

Global Personalized Medicine in Oncology Partnering Terms and Agreements 2010 to 2016 includes:

- Trends in personalized medicine in oncology dealmaking in the biopharma industry since 2010
- Analysis of personalized medicine in oncology deal structure
- Case studies of real-life personalized medicine in oncology deals
- Access to over 700 personalized medicine in oncology deals
- The leading personalized medicine in oncology deals by value since 2010
- Most active personalized medicine in oncology dealmakers since 2010
- The leading personalized medicine in oncology partnering resources

In Global Personalized Medicine in Oncology Partnering Terms and Agreements 2010 to 2016, the available contracts are listed by:

- Headline value
- Stage of development at signing
- Deal component type
- Specific therapy target
- Specific technology target

Each deal title links via Weblink to online deal records of actual personalized medicine in oncology partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

Contents:

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in Personalized Medicine in Oncology dealmaking

2.1. Introduction
2.2. Personalized Medicine in Oncology partnering over the years
2.3. Most active Personalized Medicine in Oncology dealmakers
2.4. Personalized Medicine in Oncology partnering by deal type
2.5. Personalized Medicine in Oncology partnering by therapy area
2.6. Deal terms for Personalized Medicine in Oncology partnering
2.6.1 Personalized Medicine in Oncology partnering headline values
2.6.2 Personalized Medicine in Oncology deal upfront payments
2.6.3 Personalized Medicine in Oncology deal milestone payments
2.6.4 Personalized Medicine in Oncology royalty rates

Chapter 3 - Leading Personalized Medicine in Oncology deals

3.1. Introduction
3.2. Top Personalized Medicine in Oncology deals by value
Appendix 4 - Personalized Medicine in Oncology deals by therapy area

Bladder cancer
Bone cancer
Brain cancer
Breast cancer
Cervical cancer
Colorectal cancer
Endometrial
esophageal cancer
Gastric cancer
Head and neck cancer
Kidney cancer
Leukemia
Acute lymphoblastic leukemia
Acute myelogenous leukemia
Chronic lymphocytic leukemia
Chronic myelogenous leukemia
Liver cancer
Lung cancer
Non small cell lung cancer
Lymphoma
Non Hodgkin's lymphoma
Melanoma
Mesothelioma
Metastases
Multiple myeloma
Ovarian cancer
Pancreatic cancer
Prostate cancer
Renal cell carcinoma
Sarcoma
Solid tumors
Symptoms
Oral mucositis
Testicular cancer
Thyroid cancer

Appendix 5 - Deal type definitions

About

Table of figures

Figure 1: Personalized Medicine in Oncology partnering since 2010
Figure 2: Active Personalized Medicine in Oncology dealmaking activity- 2010 to 2016
Figure 3: Personalized Medicine in Oncology partnering by deal type since 2010
Figure 4: Personalized Medicine in Oncology partnering by disease type since 2010
Figure 5: Personalized Medicine in Oncology deals with a headline value
Figure 6: Personalized Medicine in Oncology deals with an upfront value
Figure 7: Personalized Medicine in Oncology deals with a milestone value
Figure 8: Personalized Medicine in Oncology deals with a royalty rate value
Figure 9: Top Personalized Medicine in Oncology deals by value since 2010
Figure 10: Most active Personalized Medicine in Oncology dealmakers 2010 to 2016
Figure 11: Online partnering resources
Figure 12: Forthcoming partnering events

Ordering:
Order Online - [http://www.researchandmarkets.com/reports/3611455/](http://www.researchandmarkets.com/reports/3611455/)
Order by Fax - using the form below
Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit
http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: Global Personalized Medicine in Oncology Partnering Terms and Agreements 2010 to 2016
Web Address: http://www.researchandmarkets.com/reports/3611455/
Office Code: SCH3W91Z

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Quantity</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) - Single User:</td>
<td>USD 2995</td>
</tr>
<tr>
<td>CD-ROM - Single User:</td>
<td>USD 3495 + USD 58 Shipping/Handling</td>
</tr>
<tr>
<td>Electronic (PDF) - 1 - 5 Users:</td>
<td>USD 4495</td>
</tr>
<tr>
<td>CD-ROM - 1 - 5 Users:</td>
<td>USD 4995 + USD 58 Shipping/Handling</td>
</tr>
<tr>
<td>Electronic (PDF) - Site License:</td>
<td>USD 8995</td>
</tr>
<tr>
<td>CD-ROM - Site License:</td>
<td>USD 9495 + USD 58 Shipping/Handling</td>
</tr>
<tr>
<td>Electronic (PDF) - Enterprisewide:</td>
<td>USD 14995</td>
</tr>
<tr>
<td>Electronic and CD ROM (PDF) - Enterprisewide:</td>
<td>USD 15495 + USD 58 Shipping/Handling</td>
</tr>
</tbody>
</table>

* Shipping/Handling is only charged once per order.

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: [ ] Mr [ ] Mrs [ ] Dr [ ] Miss [ ] Ms [ ] Prof
First Name: ___________________________ Last Name: ___________________________
Email Address: * _______________________
Job Title: ____________________________
Organisation: _________________________
Address: ______________________________
City: _________________________________
## Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

- **Pay by credit card:** You will receive an email with a link to a secure webpage to enter your credit card details.

- **Pay by check:** Please post the check, accompanied by this form, to:
  
  Research and Markets,  
  Guinness Center,  
  Taylors Lane,  
  Dublin 8,  
  Ireland.

- **Pay by wire transfer:** Please transfer funds to:

<table>
<thead>
<tr>
<th>Description</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Account number</td>
<td>833 130 83</td>
</tr>
<tr>
<td>Sort code</td>
<td>98-53-30</td>
</tr>
<tr>
<td>Swift code</td>
<td>ULSBIE2D</td>
</tr>
<tr>
<td>IBAN number</td>
<td>IE78ULSB98533083313083</td>
</tr>
<tr>
<td>Bank Address</td>
<td>Ulster Bank, 27-35 Main Street, Blackrock, Co. Dublin, Ireland.</td>
</tr>
</tbody>
</table>

If you have a Marketing Code please enter it below:

**Marketing Code:**

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp